高风险非裔加勒比青光眼患者选择性激光小梁成形术的临床结局
这项前瞻性干预病例系列纳入具有高进展风险的开角型青光眼非裔加勒比患者,行双侧360°选择性激光小梁成形术(SLT),按术前指征分为降眼压组和减少用药组,随访至24个月。结果显示降眼压组眼压显著下降而用药不变,减少用药组用药显著减少且部分时间点眼压下降,无威胁视力不良事件。
要点
- 高进展风险非裔加勒比开角型青光眼患者单次360°SLT后24个月内眼压或用药可获显著下降。
- 降眼压组平均眼压从21.7 mmHg降至16.2-17.1 mmHg,用药无变化。
- 减少用药组平均用药从基线1.9种降至1.2-1.4种,部分时间点眼压显著降低。
核心结论
- 高进展风险的非裔加勒比开角型青光眼患者接受单次360°SLT后,至24个月随访可获有临床和统计学意义的眼压或用药减少。
研究设计与样本
- 前瞻性干预病例系列,纳入符合高进展风险标准的非裔加勒比开角型青光眼患者,行双侧360°SLT,按术前指征分降眼压组和减少用药组分析。
主要发现
- 降眼压组33只右眼平均眼压从21.7(7.5)mmHg降至随访期间16.2-17.1 mmHg(p<0.0177),用药在各时间点不变(p>0.05)。
- 减少用药组36只右眼平均用药从基线1.9(0.9)种降至随访期间每眼1.2-1.4种(p<0.0033)。
- 减少用药组平均眼压在1-6个月降至13.1(2.3)mmHg(p=0.0013),13-18个月降至14.3(2.8)mmHg(p=0.0136),其他时间点不变。
- 未发生威胁视力的不良事件。
关键数值与推荐
- 高进展风险标准包括:晚期病变、单眼青光眼盲、使用>2种药物眼压仍不达标、近期用药下进展、无法管理、负担或耐受药物。
- 降眼压组眼压下降在随访期间p<0.0177,减少用药组用药减少p<0.0033。
临床怎么用
- 对于高进展风险的非裔加勒比开角型青光眼患者,单次360°SLT可作为降低眼压或减少用药依赖的治疗选择。
局限性
- 本文为前瞻性病例系列,非对照研究,样本量有限(降眼压组33只右眼,减少用药组36只右眼),左眼结果相似但未详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To characterise clinical outcomes following selective laser trabeculoplasty (SLT) in eyes of Afro-Caribbean patients with open-angle glaucoma (OAG) at high risk for progression. METHODS: In a prospective interventional case series, patients meeting high-risk criteria (advanced disease, unilateral glaucoma blindness, inadequate intraocular pressure (IOP) on >2 medications, recent progression on medications, inability to administer, afford or tolerate medications) underwent bilateral 360° SLT and managed based on their subsequent clinical course. Patient-specific indications for SLT-IOP reduction (IOP group) or reduced reliance on medical therapy (MED group)-were recorded before treatment. IOP and medication use were recorded every 3-4 months through up to 24 months of follow-up. Outcomes were analysed separately in the IOP and MED groups. RESULTS: Among 33 right eyes (left eye outcomes were similar) in the IOP group, mean (SD) IOP was significantly reduced from 21.7 (7.5) mm Hg to 16.2-17.1 mm Hg over follow-up (p<0.0177); medication use remained unchanged (p>0.05) at all time points. Among 36 right eyes in the MED group, mean medication use was 1.9 (0.9) at baseline and ranged from 1.2 to 1.4 medications per eye through follow-up (p<0.0033), and mean IOP was significantly reduced at months 1-6 (to 13.1 (2.3) mm Hg, p=0.0013), months 13-18 (to 14.3 (2.8), p=0.0136) and unchanged at other time points. No vision-threatening adverse events occurred. CONCLUSIONS: Afro-Caribbean patients with OAG at risk for progression can achieve clinically and statistically significant reductions in IOP or medications through up to 24 months following a single 360° SLT treatment. TRIAL REGISTRATION NUMBER: NCT02375009.
引用
- Realini T, Shillingford-Ricketts H, Burt D, et al. Clinical outcomes following selective laser trabeculoplasty in Afro-Caribbean patients with glaucoma at high risk for progression. Br J Ophthalmol. 2021. PMID: 33836987. doi:10.1136/bjophthalmol-2020-317117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。